Go Deep
Pfizer Limited
Pfizer Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,245 | 23.0 | 4.01 | 0.02 | 3,688.30 |
Pfizer Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 6,531,700,000.0 | 6,292,300,000.0 | 6,450,300,000.0 | 6,423,400,000.0 |
| Net Profit | 2,044,700,000.0 | 1,998,200,000.0 | 1,418,400,000.0 | 1,890,200,000.0 |
| EPS | 44.7 | 43.7 | 31.0 | 41.3 |
Pfizer Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 25,192,700,000.0 | 22,810,000,000.0 | 21,926,900,000.0 | 24,223,200,000.0 |
| Net Profit | 7,224,300,000.0 | 7,676,000,000.0 | 5,513,300,000.0 | 6,239,300,000.0 |
| EPS | 157.9 | 167.8 | 120.5 | 136.4 |
Pfizer Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 49,218,800,000.0 | 49,111,100,000.0 | 42,287,800,000.0 | 40,007,300,000.0 | — |
| Total Liabilities | 7,189,800,000.0 | 6,937,000,000.0 | 6,332,400,000.0 | 7,934,300,000.0 | — |
| Total Equity | 42,029,000,000.0 | 42,174,100,000.0 | 35,955,400,000.0 | 32,073,000,000.0 | — |
Owes vs Owns
Pfizer Limited owed ₹0.15 for every ₹1 it owned in Mar 2026, down from ₹0.20 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.15× | 0.14× | 0.15× | 0.20× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Pfizer Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 62.7%Receivables 3.7%Inventory 9.6%Fixed assets (tangible) 3.2%Intangible assets 11.0%Other assets 9.4%
How it's funded — Mar 2026
Long-term debt 0.7%Payables 4.4%Other liabilities 9.4%Shareholders' equity 85.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3,088.4 | 2,782.6 | 2,026.6 | 1,839.7 |
| Receivables | 181.8 | 193.1 | 187.6 | 151.7 |
| Inventory | 472.7 | 475.9 | 433.7 | 417.7 |
| Fixed assets (tangible) | 157.0 | 180.0 | 151.5 | 185.8 |
| Intangible assets | 541.8 | 551.8 | 561.8 | 571.7 |
| Long-term investments | 15.2 | 13.9 | 14.3 | 13.0 |
| Other assets | 465.0 | 713.8 | 853.3 | 821.1 |
| Liabilities & equity | ||||
| Short-term debt | 2.5 | 2.5 | 2.5 | 2.5 |
| Long-term debt | 36.1 | 67.6 | 54.4 | 93.3 |
| Payables | 215.9 | 151.6 | 166.2 | 217.1 |
| Other liabilities | 464.5 | 472.0 | 410.2 | 480.6 |
| Shareholders' equity | 4,202.9 | 4,217.4 | 3,595.5 | 3,207.3 |
| Net tangible assets | 3,661.1 | 3,665.6 | 3,033.8 | 2,635.6 |
Pfizer Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 9,675,700,000.0 | 6,597,500,000.0 | 2,568,400,000.0 | 3,556,800,000.0 | — |
| Investing Activities | -5,616,700,000.0 | -713,400,000.0 | 537,000,000.0 | -360,500,000.0 | — |
| Financing Activities | -7,983,100,000.0 | -2,053,400,000.0 | -2,351,400,000.0 | -3,457,900,000.0 | — |